EXEL
NGSExelixis Inc.
Healthcare•Biotechnology
Watchlists:
Last updated: Monday 7th July 2025
46.15
+1.85 (4.18%)
Prev Close:44.3
Open:44.405
Bid:46.0
Ask:46.25
52 Week Range
21.8649.62
Volume:3,345,405
Mkt Cap:11,896 M
77
MarketXLS Rank ®
Buy
Price Target
$53.07
+15.0%
Metrics
Valuation
20.13
Range data not available
Returns
4.71%
7.25%
32.46%
108.92%
112.57%
97.48%
38.59%
Growth
EPS
QoQ
N/A
YoY
N/A
Revenue
QoQ
N/A
YoY
N/A
Free Cash Flow
QoQ
N/A
YoY
N/A
Peers
Risk
Risk Metrics
Financial Scores
0.00
12.79
Dividends
Dividend Metrics
Dividend Yields
Analyst Estimates
EPS Estimates
Target Prices
Growth Estimates
Financial Health
Cash Metrics
Liquidity Ratios
3.50
3.30
Debt Metrics
Other Metrics
Financial Scores
6.0
Technicals
Technical Oscillators
Moving Averages
Volatility Metrics
Profitability
Return Ratios
Margin Ratios
Financial Scores
Financials
Financial Statements
EXEL - Income Statement (Annual)
| Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Depreciation And Amortization | 26 M | 21 M | 14 M | 9 M | 8 M | -5 M | 1 M | 1000000.0 | ||
| General And Administrative Expense | 492 M | 543 M | 460 M | 402 M | 293 M | 228 M | 159 M | 116 M | ||
| Gross Profit Margin (profit Margin After CGS) | 2,092 M | 1,758 M | 1,553 M | 1,382 M | 951 M | 935 M | 827 M | 437 M | 185 M | 33 M |
| Impairment Of Capital Assets | 0.0 | |||||||||
| Interest Expense Non Operating | 0.0 | 9 M | 33 M | 41 M | ||||||
| Misc Other Special Charges | -133000.0 | 93000.0 | -197000.0 | -184000.0 | 912000.0 | 680000.0 | 397000.0 | -4 M | -12 M | 824000.0 |
| Net Income (loss) | 521 M | 208 M | 182 M | 231 M | 112 M | 321 M | 690 M | 154 M | -70 M | -161 M |
| Net Income Common Stockholders | 521 M | 208 M | 182 M | 231 M | 112 M | 321 M | 690 M | 154 M | -70 M | -161 M |
| Net Income Continuous Operations | 521 M | 208 M | 182 M | 231 M | 112 M | 321 M | 690 M | 154 M | -70 M | -161 M |
| Net Non Operating Interest Income Expense | 77 M | 87 M | 33 M | 8 M | 20 M | 28 M | 13 M | -4 M | -30 M | -41 M |
| Operating Income | 605 M | 171 M | 201 M | 287 M | 110 M | 369 M | 439 M | 166 M | -28 M | -120 M |
| Operating Income Before Depreciation (EBITDA) | 710 M | 283 M | 255 M | 300 M | 119 M | 406 M | 0.0 | 167 M | -28 M | -77 M |
| Operating Expense | 1,403 M | 1,587 M | 1,352 M | 1,095 M | 841 M | 565 M | 389 M | 287 M | 220 M | 154 M |
| Other Gand A | 492 M | 543 M | 460 M | 402 M | 293 M | 228 M | 159 M | 116 M | ||
| Other Impairment Of Capital Assets | 52 M | |||||||||
| Other Operating Expenses | -2 M | -3 M | -2 M | 0.0 | ||||||
| Promotion And Advertising | 32 M | 25 M | 18 M | -15 M | ||||||
| Research Expense | 910 M | 1,044 M | 892 M | 694 M | 548 M | 337 M | 182 M | 112 M | 96 M | 96 M |
| Restructring And Mn A Income | 34 M | -32000.0 | 914000.0 | 1 M | ||||||
| Salaries And Wages | -41 M | |||||||||
| Selling And Marketing Expense | 44 M | 40 M | 42 M | 32 M | 25 M | 18 M | 206 M | 57 M | ||
| Selling Expense | 206 M | 57 M | ||||||||
| Total Income Available For Interest Expense (EBIT) | 682 M | 258 M | 234 M | 287 M | 110 M | 398 M | 439 M | 167 M | -37 M | -121 M |
| Total Revenues | 2,169 M | 1,830 M | 1,611 M | 1,435 M | 988 M | 968 M | 854 M | 452 M | 191 M | 37 M |
| Total Expenses | 1,479 M | 1,659 M | 1,410 M | 1,148 M | 877 M | 598 M | 415 M | 302 M | 226 M | 158 M |
| Total Revenue | 2,169 M | 1,830 M | 1,611 M | 1,435 M | 988 M | 968 M | 854 M | 452 M | 191 M | 37 M |
| Avgshs | 290 M | 318 M | 322 M | 315 M | 308 M | 303 M | 298 M | 294 M | 251 M | 209 M |
| Avgshsdt | 296 M | 321 M | 325 M | 322 M | 318 M | 315 M | 313 M | 312 M | 251 M | 210 M |
| Basiceps | 1.8 | 0.65 | 0.57 | 0.73 | 0.36 | 1.06 | 2.32 | 0.52 | -0.28 | |
| Basicepscont | 1.8 | 0.65 | 0.57 | 0.73 | 0.36 | 1.06 | 0.52 | -0.28 | ||
| Cor | 76 M | 73 M | 58 M | 53 M | 36 M | 33 M | 26 M | 15 M | 7 M | 4 M |
| Depamor | 14 M | 9 M | 8 M | 0.0 | ||||||
| Dileps | 1.76 | 0.65 | 0.56 | 0.72 | 0.35 | 1.02 | 2.21 | 0.49 | -0.28 | -0.77 |
| Dilepscont | 1.76 | 0.65 | 0.56 | 0.72 | 0.35 | 1.02 | 0.49 | |||
| Intinc | 77 M | 87 M | 33 M | 8 M | 20 M | 28 M | 13 M | 5 M | 3 M | |
| Netincdisc | 521 M | 208 M | 182 M | 231 M | 112 M | 321 M | 690 M | 154 M | -70 M | -161 M |
| Othincexp | 52 M | -93000.0 | -197000.0 | 184000.0 | -912000.0 | -680000.0 | -397000.0 | 4 M | 12 M | -824000.0 |
| Pretaxinc | 682 M | 258 M | 234 M | 294 M | 131 M | 398 M | 452 M | 159 M | -70 M | -161 M |
| Resdev | 910 M | 1,044 M | 892 M | 694 M | 548 M | 337 M | 182 M | 112 M | 96 M | 96 M |
| Restruct | 34 M | -32000.0 | 914000.0 | 1 M | ||||||
| Sga | 492 M | 543 M | 460 M | 402 M | 293 M | 228 M | 206 M | 159 M | 116 M | 57 M |
| Shsout | 280 M | 303 M | 324 M | 319 M | 312 M | 305 M | 300 M | 296 M | 291 M | 228 M |
| Specincchg | -34 M | 32000.0 | -914000.0 | -1 M | ||||||
| Taxprov | 160 M | 50 M | 52 M | 63 M | 19 M | 77 M | -238 M | 4 M | 55000.0 |
Call: 1-877-778-8358 
Welcome! I'm Ankur, the founder and CEO of MarketXLS. With more than ten years of experience, I have assisted over 2,500 customers in developing personalized investment research strategies and monitoring systems using Excel.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
Implement "your own" investment strategies in Excel with thousands of MarketXLS functions and templates.
MarketXLS provides all the tools I need for in-depth stock analysis. It's user-friendly and constantly improving. A must-have for serious investors.
I have been using MarketXLS for the last 6+ years and they really enhanced the product every year and now in the journey of bringing in AI...
MarketXLS is a powerful tool for financial modeling. It integrates seamlessly with Excel and provides real-time data.
I have used lots of stock and option information services. This is the only one which gives me what I need inside Excel.